Vicus Capital Repligen Corp Transaction History
Vicus Capital
- $1.12 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding RGEN
# of Institutions
487Shares Held
54.4MCall Options Held
341KPut Options Held
235K-
Black Rock Inc. New York, NY7.57MShares$944 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$797 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$629 Million0.01% of portfolio
-
State Street Corp Boston, MA1.62MShares$203 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.42MShares$177 Million1.34% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $6.92B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....